Arca
Skip to content
Tools
Tools

Label Changes: Inluriyo (imlunestrant tosylate)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Inluriyo label DailyMed has published, from Eli Lilly and Company, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 4
  • Sections changed, version 7 to 8: 9

What changed from version 7 to version 8

Jun 10, 2026 to Oct 1, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 63 words added, 3 removed
  2. Dosage and administrationChanged · 104 words added, 45 removed
  3. Adverse reactionsChanged · 758 words added, 31 removed
  4. Use in specific populationsChanged · 194 words added
  5. DescriptionChanged · 2 words added, 2 removed
  6. Clinical studiesChanged · 755 words added, 180 removed
  7. How suppliedChanged · 2 words added
  8. Patient counseling informationChanged · 102 words added, 7 removed
  9. Patient informationChanged · 147 words added, 8 removed

Indications and usage

Changed63 words added, 3 removed
1 INDICATIONS AND USAGE
INLURIYO is indicated:
INLURIYO isas indicatedmonotherapy, for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy [see Dosage and Administration (2.1)].
in combination with abemaciclib for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy [see Dosage and Administration (2.1)].

Dosage and administration

Changed104 words added, 45 removed
1 unchanged line
2.1 Patient Selection
Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with INLURIYO based on the presence of ESR1 mutation(s) in a plasma specimen using an FDA-approvedauthorized test [see Indications and Usage (1) and Clinical Studies (14.1)].
Information on FDA-approvedauthorized tests for the detection of ESR1 mutations in breast cancer is available at: https://www.fda.gov/CompanionDiagnostics.
2.2 Recommended Dosage and Administration
The recommended dosage of INLURIYO, as monotherapy or in combination with abemaciclib, is 400 mg orally once daily until disease progression or unacceptable toxicity.
Take on an empty stomach at least 2 hours before food, or 1 hour after food [see Clinical Pharmacology (12.3)]. Take INLURIYO tablets at approximately the same time daily. Swallow the tablets whole. Do not split, crush, or chew the tablets.
Pre/perimenopausal women and men should receive a gonadotropin-releasing hormone agonist (GnRH) according to current clinical practice standards.
If patient misses a dose by 6 or more hours or vomits, instruct the patient to take the next dose the following day at its scheduled time.
Refer to the Prescribing Information for the recommended dosage of abemaciclib when used in combination with INLURIYO.
2.3 Dosage Modifications for Adverse Reactions
2 unchanged lines
Permanently discontinue INLURIYO in patients who are unable to tolerate 200 mg once daily.
Refer to the Prescribing Information for dosage modification guidelines and other relevant safety information for abemaciclib when used in combination with INLURIYO.
Table 1: INLURIYO Dosage ModificationModifications - Adverse Reactions (except hepatotoxicity)
Grade | INLURIYO Dosage Modifications
Persistent or recurrent Grade 2 that does not resolve with maximal supportive measures within 7 days to baseline or Grade 1 | SuspendWithhold until toxicity resolves to baseline or ≤Grade 1. Resume INLURIYO at the same dose level.
Grade 3 or 4 (except non-hepatic asymptomatic laboratory changes) | SuspendWithhold until toxicity resolves to baseline or ≤Grade 1. Resume INLURIYO at next lower dose level.
Table 2: INLURIYO Dosage Modification - Hepatotoxicity
Abbreviation: ALT = alanine aminotransferase, AST = aspartate aminotransferase, TBL=total bilirubin, ULN = upper limit of normal.
Monitor alanine aminotransferase (ALT)/aspartate aminotransferase (AST) during imlunestrant therapy as clinically indicated.
Monitor ALT/AST during imlunestrant therapy as clinically indicated.
Liver Transaminase | INLURIYO Dosage Modifications
Persistent or Recurrent: AST/ALT >3.0-5.0×ULN | SuspendWithhold until toxicity resolves to baseline or to >ULN-3.0×ULN. Resume INLURIYO at the same dose level.
If AST/ALT at baseline is within the normal range: AST/ALT >5.0-20×ULN Or If AST/ALT at baseline is above ULN: AST/ALT ≥3 × baseline (if AST/ALT≥1.5 x ULN at baseline) Or AST/ALT >8 × ULN (whichever is the lower threshold) | SuspendWithhold until toxicity resolves to baseline or to >ULN-3.0×ULN. Resume INLURIYO at next lower dose level or discontinue if receiving 200 mg daily.
AST/ALT >20.0×ULN Or ALT or AST ≥ 3 × ULN concurrent with TBL ≥ 2 × ULN (if ALT or AST < 1.5 × ULN at baseline), in the absence of cholestasis Or ALT or AST ≥ 2 × baseline concurrent with TBL ≥ 2 × ULN (if ALT or AST ≥ 1.5 × ULN at baseline), in the absence of cholestasis | DiscontinuePermanently discontinue INLURIYO.
2.4 Dosage in Patients with Hepatic Impairment
The recommended dosage of INLURIYO for patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment is 200 mg once daily. Monitor for increased adverse reactions [see Clinical Pharmacology (12.3)].
Refer to the Prescribing Information for dosage modification for severe hepatic impairment for abemaciclib when used in combination with INLURIYO.
2.5 Dosage Modifications for Drug Interactions
1 unchanged line
Avoid concomitant use with strong CYP3A inhibitors. If concomitant use cannot be avoided, decrease the INLURIYO dosage to 200 mg once daily [see Drug Interactions (7.1)].
Refer to the Prescribing Information for dosage modification for strong CYP3A Inhibitors for abemaciclib when used in combination with INLURIYO.
Strong CYP3A Inducers
1 unchanged line

Adverse reactions

Changed758 words added, 31 removed
2 unchanged lines
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
ER+, HER2-, ESR1 -mutated Advanced or Metastatic Breast Cancer
INLURIYO as Monotherapy
The safety of INLURIYO was evaluated in 651 patients with ER+, HER2- locally advanced or metastatic breast cancer previously treated with endocrine therapy with or without a prior CDK4/6 inhibitor in EMBER-3 [see Clinical Studies (14.1)]. Patients received INLURIYO 400 mg orally, once daily (n=327), or standard of care (n=324) consisting of either fulvestrant (n=292) or exemestane (n=32). Among patients who were treated with INLURIYO, the median duration of exposure was 5.6 months (range: 0.2 to 28.6 months) in EMBER-3.
Serious adverse reactions occurred in 10% of patients who received INLURIYO. Serious adverse reactions in > 1% of patients included pleural effusion (1.2%). Fatal adverse reactions occurred in 1.8% of patients who received INLURIYO, including cardiac arrest, acute myocardial infarction, right ventricular failure, hypovolemic shock, and upper gastrointestinal hemorrhage (each 0.3%).
Permanent treatment discontinuation of INLURIYO due to an adverse reaction occurred in 4.6% of patients. Adverse reactions which resulted in permanent discontinuation of INLURIYO included increased alanine aminotransferase (ALT) (0.9%), abdominal pain, fatigue, fractured sacrum, hepatotoxicity, neuropathy peripheral, and pyrexia (each 0.3%).
Dosage interruption of INLURIYO due to an adverse reaction occurred in 10% of patients. Adverse reactions which required dosage interruption in >0.5% were vomiting (1.5%); increased aspartate aminotransferase (AST), and COVID-19 (each 0.9%); and increased alanine aminotransferaseALT, anemia, diarrhea, decreased neutrophil count, and pyrexia (each 0.6%).
Dose reductions of INLURIYO due to an adverse reaction occurred in 2.4% of patients. Adverse reactions which required dose reductions were increased aspartate aminotransferaseAST (0.6%); and increased alanine aminotransferaseALT, anemia, fatigue, interstitial lung disease, nausea, neutropenia, and vomiting (each 0.3%).
The most common (≥10%) adverse reactions, including laboratory abnormalities, were hemoglobin decreased hemoglobin, musculoskeletal pain, decreased calcium, decreased, neutrophils decreased, AST increased AST, fatigue, diarrhea, increased ALT, increased, triglycerides increased, nausea, platelets decreased platelets, constipation, cholesterol increased cholesterol, and abdominal pain.
Table 3 summarizes the adverse reactions in EMBER-3.
16 unchanged lines
Table 4: Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received INLURIYO in EMBER-3
a Graded according to NCI CTCAE version 5.0
b The denominator used to calculate the rate varied from 252 to 325 based on the number of patients with a baseline value and at least one post-treatment value.
7 unchanged lines
Calcium decreased | 26 | 0 | 19 | 0.6
Aspartate aminotransferase increased | 25 | 1.9 | 27 | 2.3
AST increased | 25 | 1.9 | 27 | 2.3
Alanine aminotransferase increased | 21 | 1.3 | 23 | 1.0
ALT increased | 21 | 1.3 | 23 | 1.0
Triglycerides increased | 21 | 0 | 22 | 1.2
Cholesterol increased | 10 | 0 | 12 | 0
INLURIYO in Combination with Abemaciclib
The safety of INLURIYO in combination with abemaciclib was evaluated in 535 patients with ER+, HER2- locally advanced or metastatic breast cancer previously treated with endocrine therapy with or without a prior CDK4/6 inhibitor in EMBER-3 [see Clinical Studies (14)]. Patients received INLURIYO 400 mg orally once daily in combination with abemaciclib 150 mg twice daily (N=208), or INLURIYO monotherapy 400 mg, once daily (n=327). Among patients who were treated with INLURIYO in combination with abemaciclib, the median duration of exposure was 7.7 months (range 1 day to 25.3 months).
Serious adverse reactions occurred in 21% of patients who received INLURIYO in combination with abemaciclib. Serious adverse reactions in >1% of patients included pneumonia (2.4%), abdominal pain, and renal failure (each 1.4%). Fatal adverse reactions occurred in 3.8% of patients who received INLURIYO in combination with abemaciclib, including pneumonia (1.4%), myocardial infarction, interstitial lung disease, and sepsis (0.5% each).
Permanent treatment discontinuation of INLURIYO due to an adverse reaction occurred in two patients (1%). The adverse reactions which required permanent discontinuation were increased ALT and anemia (0.5% each).
Dosage interruptions of INLURIYO due to an adverse reaction occurred in 50% of patients. Adverse reactions which required dosage interruptions of INLURIYO in ≥2% of patients included diarrhea (14%), neutropenia (9%), decreased neutrophil count (6%), nausea (6%), anemia (6%), increased ALT (2.4%), and vomiting (2.4%).
Dose reductions of INLURIYO due to an adverse reaction occurred in 18% of patients. Adverse reactions which required dose reductions of INLURIYO in ≥ 1% of patients included diarrhea (6%), neutropenia (1.9%), nausea (1.9%), increased ALT (1.9%), and decreased neutrophil count (1.4%).
The most common (≥10%) adverse reactions, including laboratory abnormalities, were decreased neutrophils, diarrhea, decreased hemoglobin, decreased lymphocytes, nausea, decreased platelets, fatigue, increased triglycerides, infections, increased AST, increased creatinine, increased ALT, vomiting, musculoskeletal pain, abdominal pain, decreased appetite, increased cholesterol, rash, cough, headache, and decreased weight.
Table 5 summarizes the adverse reactions in EMBER-3.
Table 5: Adverse Reactions (≥10%) in Patients Who Received INLURIYO in Combination with Abemaciclib in EMBER-3
a Adverse reactions were graded using NCI CTCAE version 5.0.
b Includes other related terms
Adverse Reactiona | INLURIYO plus Abemaciclib N=208 | INLURIYO N=327
All Grades % | Grades 3 or 4 % | All Grades % | Grades 3 or 4 %
Gastrointestinal Disorders
Diarrhea | 86 | 9 | 23 | 0.3
Nausea | 51 | 1.9 | 18 | 0.3
Vomiting | 32 | 0.5 | 10 | 0.6
Abdominal painb | 24 | 1.9 | 11 | 0.3
General Disorders and Administration Site Conditions
Fatigueb | 41 | 5 | 24 | 0.3
Infections and Infestations
Infectionsb | 36 | 7 | 25 | 3.4
Musculoskeletal Disorders
Musculoskeletal painb | 25 | 1.4 | 31 | 2.8
Metabolism and Nutrition Disorders
Decreased appetiteb | 22 | 1 | 9 | 0.3
Skin and Subcutaneous Tissue Disorders
Rashb | 14 | 1.4 | 4.9 | 0
Respiratory, Thoracic and Mediastinal Disorders
Coughb | 13 | 0 | 9 | 0
Nervous System Disorders
Headacheb | 10 | 0.5 | 9 | 0
Investigations
Weight decreased | 10 | 0 | 4.6 | 0
Clinically relevant adverse reactions (<10%) in patients who received INLURIYO in combination with abemaciclib included: constipation (9%), stomatitis (9%), fever (9%), urinary tract infection (8%), dizziness (8%), hot flush (6%), insomnia (6%), arrhythmia (6%), alopecia (5%), back pain (4.8%), venous thromboembolic event (4.8%) and interstitial lung disease or pneumonitis (2.9%).
Table 6 summarizes the laboratory abnormalities in EMBER-3.
Table 6: Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received INLURIYO in Combination with Abemaciclib in EMBER-3
a Graded according to NCI CTCAE version 5.
b The denominator used to calculate the frequency varied from 178 to 205 based on the number of patients with a baseline value and at least one post-treatment value.
Lab Abnormality a | INLURIYO plus Abemaciclib b | INLURIYO b
All Grades % | Grades 3 or 4 % | All Grades % | Grades 3 or 4 %
Hematology
Neutrophils decreased | 86 | 21 | 28 | 4.3
Hemoglobin decreased | 81 | 9 | 34 | 2.2
Lymphocytes decreased | 58 | 9 | 29 | 2.2
Platelets decreased | 48 | 2.4 | 18 | 2.8
Chemistry
Triglycerides increased | 40 | 2.3 | 22 | 0
AST increased | 36 | 2.5 | 27 | 1.9
Creatinine increased | 36 | 1.1 | 6 | 0.3
ALT increased | 33 | 5 | 22 | 1.3
Cholesterol increased | 18 | 0 | 12 | 0.4

Use in specific populations

Changed194 words added
2 unchanged lines
Risk Summary
Refer to the Prescribing Information of abemaciclib when administered in combination with INLURIYO for pregnancy information.
Based on findings in animals and its mechanism of action, INLURIYO can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available human data on INLURIYO use in pregnant women to inform the drug-associated risk. In an animal reproduction study, oral administration of imlunestrant to pregnant rats during the period of organogenesis led to embryo-fetal mortality and structural abnormalities at maternal exposures below the human exposure at the recommended dose based on AUC (see Data). Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
4 unchanged lines
8.2 Lactation
Refer to the Prescribing Information of abemaciclib when administered in combination with INLURIYO for lactation information. When used in combination, advise patients to not breastfeed during treatment and for the longest post-treatment duration recommended in the Prescribing Information of the individual products.
Risk Summary
1 unchanged line
8.3 Females and Males of Reproductive Potential
Refer to the Prescribing Information of abemaciclib when administered in combination with INLURIYO for contraception and infertility information. When used in combination, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of the individual products.
INLURIYO can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].
11 unchanged lines
8.5 Geriatric Use
Of 327 patients who received INLURIYO monotherapy in the EMBER-3 study, 118 patients were ≥ 65 years of age and 37 patients were ≥ 75 years of age. No overall differences in safety or effectiveness of INLURIYO monotherapy have been observed between patients 65 years of age and older and younger adult patients.
Of the 208 patients who received INLURIYO in combination with abemaciclib in the EMBER-3 study, 90 patients were ≥65 years of age and 27 patients were ≥75 years of age. There was a higher rate of nausea in patients aged 65 years or older (59%) compared with younger patients (44%). The EMBER-3 study did not include sufficient numbers of patients 65 years of age and older with ESR1 mutations treated with INLURIYO in combination with abemaciclib to determine whether they respond differently than younger patients.
8.6 Hepatic Impairment
1 unchanged line

Description

Changed2 words added, 2 removed
11 DESCRIPTION
INLURIYO tablets contain imlunestrant, an estrogen receptor antagonist. The chemical name for imlunestrant tosylate is (5R)-5-(4-(2-(3-(flouromethylfluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-(1)benzopyrano(4,3-c)quinolin-2-ol, tosylate salt (1:1). Imlunestrant tosylate is a white to practically white to yellow powder with the empirical formula C29H24F4N2O3.C7H8O3S and a molecular weight 696.71 g/mol. The aqueous solubility of imlunestrant tosylate is slightly soluble at low pH, insoluble at neutral pH, and sparingly soluble at high pH. The chemical structure of imlunestrant tosylate is shown below:
INLURIYO are tablets are for oral administration. Each INLURIYO tablet is available as capsule-shaped, film-coated tablet that contains 200 mg imlunestrant (equivalent to 265.66 mg imlunestrant tosylate). The tablet contains the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, and microcrystalline cellulose. The tablets are coated using a common white coating, which consists of polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

Clinical studies

Changed755 words added, 180 removed
14 CLINICAL STUDIES
ER+, HER2-, ESR1 -mutated Locally Advanced or Metastatic Breast Cancer
The efficacy of INLURIYO was evaluated in EMBER-3 (NCT04975308), a randomized, open-label, active-controlled, multicenter trial that enrolled 874 adult patients with ER+, HER2- locally advanced or metastatic breast cancer of which 323 patients had ESR1 mutations (ESR1m), who were previously treated with an aromatase inhibitor either alone or in combination with a CDK4/6 inhibitor. Patients were excluded if they were eligible to receive a PARP inhibitor. Patients were required to have progressed:
Within 12 months of completing neoadjuvant or adjuvant aromatase inhibitor therapy with no systemic treatment for recurrent disease or
Greater than 12 months after neoadjuvant or adjuvant endocrine therapy or de novo metastatic disease and had progressed on only one line of aromatase inhibitor therapy.
Patients were randomized 1:1:1 to
INLURIYO 400 mg orally once daily; or
investigator's choice of endocrine therapy [fulvestrant 500 mg intramuscularly on days 1, 15, 29, and once monthly thereafter or exemestane 25 mg orally once daily]; or
INLURIYO 400 mg once daily in combination with abemaciclib 150 mg orally twice daily.
Patients were randomized 1:1:1 to INLURIYO 400 mg orally once daily; or investigator's choice of endocrine therapy [fulvestrant 500 mg IM on days 1, 15, 29, and once monthly thereafter (n=111) or exemestane 25 mg orally once daily (n=6)]; or an additional investigational combination regimen. Randomization was stratified by previous treatment with CDK4/6 inhibitor (yes vs no), presence of visceral metastasis (yes vs no), and region (East Asia vs North America/Western Europe vs Others). ESR1m status was determined by blood circulating tumor deoxyribonucleic acid (ctDNA) analysis using the Guardant360 CDx assay and was limited to specific ESR1 mutations in the ligand binding domain. Patients were treated until disease progression or unacceptable toxicity.
INLURIYO as Monotherapy
The major efficacy outcome was investigator assessed progression-free survival (PFS) according to RECIST v1.1. Other efficacy measures included overall survival (OS), blinded independent review committee (BIRC)-assessed PFS, and objective response rate (ORR).
The major efficacy outcomes for INLURIYO monotherapy were investigator-assessed progression-free survival (PFS) according to RECIST v1.1 in the overall population and in the population of patients whose tumors had an ESR1m. Other efficacy measures included overall survival (OS), blinded independent review committee (BIRC)-assessed PFS, and objective response rate (ORR). A statistically significant difference in PFS in the overall population was not observed; however, there was a statistically significant difference in PFS in the ESR1m population for INLURIYO monotherapy compared to investigator's choice of endocrine therapy (fulvestrant or exemestane) indicating the PFS benefit of INLURIYO monotherapy was limited to the ESR1m population.
Among the patients on the INLURIYO arm or investigator's choice of endocrine therapy who were positive for ESR1m (N=256), the median age was 61 years (range: 28-85 years); all patients were female, of which 11% were pre/perimenopausal; 61% were White, 26% Asian, 4% Black, 4% were American Indian or Alaskan Native, 4.7% missing, 0.8% multiple, 19% were Hispanic/Latino; and baseline ECOG performance status was 0 (63%) or 1 (37%). Most patients had visceral metastasis (59%) at baseline. Of the patients enrolled, 21% had received no endocrine therapy and 79% had received one line of endocrine therapy in the advanced or metastatic setting. Overall, 70% of patients were treated with a prior CDK4/6i6 inhibitor, 2.3% treated in the adjuvant setting and 67% treated in the advanced or metastatic setting.
The efficacy results from these patients are summarized in Table 5 and Figure 1. There was a statistically significant difference in investigator-assessed PFS in the ESR1m population for INLURIYO compared to investigator's choice of endocrine therapy (fulvestrant or exemestane). PFS assessment based on a BIRC was consistent with the investigator assessment. At the time of PFS analysis, overall survival data was immature with 31% of deaths in the ESR1m population.
Efficacy results for the ESR1m population are summarized in Table 7 and Figure 1. PFS assessment in the ESR1m population based on a BIRC was consistent with the investigator assessment. At the time of PFS analysis, overall survival data was immature with 31% of deaths in the ESR1m population.
Table 5: Efficacy Results for Patients with ESR1m in EMBER-3
Table 7: Efficacy Results for INLURIYO Monotherapy Compared with Fulvestrant/Exemestane in Patients with ESR1m in EMBER-3
a Investigator Assessed
10 unchanged lines
Patients with Measurable Disease | 112 | 91
ORR (95% CI) | 14.3% (7.8, 20.821) | 7.78% (2.2, 13.2)
Complete response rate, % | 0.9% | 0
Partial response rate, % | 13.4% | 7.78%
Figure 1: Kaplan-Meier Plot of Investigator-Assessed PFS for Patients with ESR1 m, Treated with INLURIYO Monotherapy or Fulvestrant/Exemestane in EMBER-3
INLURIYO in Combination with Abemaciclib
The major efficacy outcome for INLURIYO in combination with abemaciclib was investigator-assessed PFS according to RECIST v1.1 in the overall population. Other efficacy measures included OS, BIRC-assessed PFS, and ORR. While the comparison of PFS between INLURIYO in combination with abemaciclib and INLURIYO monotherapy in the overall population was statistically significant, a PFS improvement was not demonstrated for INLURIYO monotherapy compared to investigator's choice of endocrine therapy in either the overall or ESR1m not detected populations, indicating that the benefit for INLURIYO monotherapy was only observed in the ESR1m population. Therefore, exploratory analyses of PFS, OS and ORR in the ESR1m population comparing INLURIYO in combination with abemaciclib and INLURIYO monotherapy were performed.
Among the patients on the INLURIYO in combination with abemaciclib arm or the INLURIYO monotherapy arm who were positive for ESR1m (n=159), the median age was 62 years (range: 31-85 years); all patients were female, of which 12% were pre/perimenopausal; 60% were White, 27% Asian, 5% Black, 0.6% were American Indian or Alaskan Native, 0.6% multiple races, 7% missing, 12% were Hispanic/Latino, 75% not Hispanic/Latino, 13% not reported/missing; and all patients had a baseline ECOG performance status of 0 (66%) or 1 (34%). Most patients had visceral metastasis (58%) at baseline. Of the patients enrolled, all received a prior line of endocrine therapy and 81% had received one line of endocrine therapy in the advanced or metastatic setting. Overall, 79% of patients were treated with a prior CDK4/6 inhibitor, 4.4% were treated in the adjuvant setting and 74% were treated in the advanced or metastatic setting. Among the patients who had received prior CDK4/6 inhibitors, the specific CDK4/6 inhibitor received was palbociclib 65%, ribociclib 28%, and abemaciclib 6%.
The exploratory analyses results in the ESR1m population are summarized in Table 8 and Figure 2. PFS assessment in the ESR1m population based on a BIRC was consistent with the investigator assessment. At the time of interim analysis, overall survival data was immature with 35% of deaths in the ESR1m population.
Table 8: Efficacy Results for INLURIYO in Combination with Abemaciclib Compared with INLURIYO Monotherapy in Patients with ESR1m in EMBER-3
a Investigator Assessed
b per RECIST v1.1
c Based on the stratified Cox proportional hazard model
| INLURIYO + Abemaciclib N=67 | INLURIYO N=92
Progression-free Survival (PFS) a,b
Number of PFS Events, n (%) | 36 (54) | 71 (77)
Median in months (95% CI) | 11.1 (7.4, 13.7) | 5.5 (3.8, 7.2)
Hazard Ratio (95% CI)c | 0.53 (0.35, 0.80)
Objective Response Rate a, b
Patients with Measurable Disease | 54 | 74
ORR (95% CI) | 35% (22, 48) | 15% (7, 23)
Complete response rate | 1.9% | 1.4%
Partial response rate | 33% | 14%
Figure 2: Kaplan-Meier Plot of Investigator-Assessed PFS for Patients with ESR1 m, Treated with INLURIYO in Combination with Abemaciclib or INLURIYO Monotherapy in EMBER-3

How supplied

Changed2 words added
1 unchanged line
How Supplied
INLURIYO 200 mg tablets are white, film coated, capsule-shaped tablets with “LILLY” on one side and “1717” and an elongated 4-point starburst on the other side.
INLURIYO 200 mg tablets are supplied in either a 28-count or 56-count bottle configuration.
6 unchanged lines

Patient counseling information

Changed102 words added, 7 removed
6 unchanged lines
Advise females of reproductive potential to use effective contraception during treatment with INLURIYO and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with INLURIYO and for 1 week after the last dose [see Use in Specific Populations (8.3)].
Refer to the Prescribing Information of abemaciclib when administered in combination with INLURIYO for pregnancy and contraception information. When used in combination, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of the individual products.
Lactation
Advise women not to breastfeed during treatment with INLURIYO and for 1 week after the last dose [see Use in Specific Populations (8.2)].
Refer to the Prescribing Information of abemaciclib when administered in combination with INLURIYO for lactation information. When used in combination, advise patients to not breastfeed during treatment and for the longest post-treatment duration recommended in the Prescribing Information of the individual products.
Infertility
3 unchanged lines
Dosing Instructions
Instruct patients to take INLURIYO at approximately the same time each day and to swallow the tablet(s) whole. Tablets should not be chewed, crushed, or split prior to swallowing [see Dosage and Administration (2.12)].
Advise patients to take INLURIYO without food, either 2 hours before food or 1 hour after food [see Dosage and Administration (2.12)].
Instruct patient that if a dose of INLURIYO is missed by more than 6 hours or vomiting occurs, skip the dose and take the next dose the following day at its regularly scheduled time [see Dosage and Administration (2.12)].
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA
Copyright © 2025, 2026, Eli Lilly and Company. All rights reserved.
Pat.: www.lilly.com/patents
INL-0002-USPI-20251006
INL-0003-USPI-20260918

Patient information

Changed147 words added, 8 removed
This Patient Information has been approved by the U.S. Food and Drug Administration | IssuedRevised: October 202509/2026
PATIENT INFORMATION INLURIYOTMINLURIYO® (en-loo-ree-yoh) imlunestrant tablets
What is INLURIYO? INLURIYO is a prescription medicine that is used alone or in combination with the medicine abemaciclib to treat adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has progressed after at least 1 line of endocrine therapy. Your healthcare provider will perform a test to make sure that INLURIYO is right for you. When INLURIYO is used in combination with abemaciclib, read the Patient Information for abemaciclib. It is not known if INLURIYO is safe and effective in children.
Before taking INLURIYO, tell your healthcare provider about all of your medical conditions including if you: have liver problems. are pregnant or plan to become pregnant. INLURIYO can harm your unborn baby.
Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with INLURIYO. Use effective birth control (contraception) during treatment with INLURIYO and for 1 week after the last dose. Your healthcare provider will tell you how long you should use birth control (contraception) after combination treatment with INLURIYO and abemaciclib. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with INLURIYO.
Males with female partners who are able to become pregnant: Use effective birth control (contraception) during treatment with INLURIYO and for 1 week after the last dose. are breastfeeding or plan to breastfeed. It is not known if INLURIYO passes into breastmilk. Do not breastfeed during treatment with INLURIYO and for 1 week after the last dose. Your healthcare provider will tell you how long you should not breastfeed after combination treatment with INLURIYO and abemaciclib.
Tell your healthcare provider about all of the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements. INLURIYO and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.
How should I take INLURIYO? Take INLURIYO exactly as your healthcare provider tells you. Do not stop taking INLURIYO or change the dose unless your healthcare provider tells you to. Take INLURIYO 1 time a day at about the same time each day. Take INLURIYO on an empty stomach, at least 2 hours before food or 1 hour after food. Swallow INLURIYO tablets whole. Do not chew, crush, or split the tablets. If you miss a dose of INLURIYO by 6 or more hours or vomit after taking INLURIYO, do not take another dose on that day. Take your next dose the following day at your regularly scheduled time.
What are the possible side effects of INLURIYO? The most common side effects of INLURIYO when taken alone include:
decreased hemoglobin (anemia) muscle and joint pain decreased white blood cell counts increased liver function tests decreased calcium blood levels tiredness diarrhea increased triglyceride and cholesterol blood levels. Your healthcare provider will check your blood levels before and during treatment with INLURIYO. | nausea decreased platelet counts constipation stomach-area (abdominal) pain
The most common side effects of INLURIYO when taken with abemaciclib include:
decreased white blood cell counts diarrhea decreased hemoglobin (anemia) nausea decreased platelet counts tiredness increased triglycerides and cholesterol blood levels. Your healthcare provider will check your blood levels before and during treatment with INLURIYO. infections | increased liver function tests increased creatinine blood levels vomiting muscle and joint pain stomach-area (abdominal) pain decreased appetite rash cough headache weight loss
Your healthcare provider may change your dose, temporarily stop, or completely stop treatment with INLURIYO if you develop certain side effects. INLURIYO may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of INLURIYO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
2 unchanged lines
General information about the safe and effective use of INLURIYO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use INLURIYO for a condition for which it was not prescribed. Do not give INLURIYO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about INLURIYO.
What are the ingredients in INLURIYO? Active ingredient: imlunestrant Inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, and microcrystalline cellulose. The tablet coating contains polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. INLURIYO is a trademark of Eli Lilly and Company. All rights reserved. Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA Copyright © 2025, 2026, Eli Lilly and Company. All rights reserved. For more information, go to www.INLURIYO.com or call 1-800-545-5979
INL-0002-PPI-20251006
INL-0003-PPI-20260918

Unchanged: Dosage forms and strengths, Contraindications, Warnings and precautions, Drug interactions, Clinical pharmacology, Nonclinical toxicology, PACKAGE LABEL – Inluriyo 200 mg 56 count bottle.

Every version

4 versions of set 5bc172e4-e8a2-441a-be52-279a7f890196, newest first.
VersionPublished on DailyMedCompareSPL file
8Oct 1, 2026Shown belowDownload .zip
7Jun 10, 2026With version 6Download .zip
6Feb 25, 2026With version 4Download .zip
4Nov 17, 2025First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.